Key facts
- This page summarizes Jon Congleton's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 21 Aug 2023, 16:03.
Jon Congleton - 17 Aug 2023 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- MLYS
- Reported as of
- 17 Aug 2023
- Net transaction value
- +$27,225
- SEC form
- 4
- Accepted by SEC
- 21 Aug 2023, 16:03:20 UTC
- Prior SEC filing
- 11 Aug 2023
- Next SEC filing
- 08 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adam Levy, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jon Congleton filed Form 4 for Mineralys Therapeutics, Inc. (MLYS) on 21 Aug 2023.
Change
- Previous filing in this sequence was filed on 11 Aug 2023.
- Current net transaction value: +$27,225.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MLYS
transaction
Common Stock
Purchase
- Transaction value
- $27,225
- Shares
- +2,250
- Change %
- +0.22%
- Price
- $12.10
- Shares after
- 1,042,568
- Date
- 17 Aug 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The price reported is the weighted-average purchase price, purchased in multiple transactions at prices ranging from $12.02 to $12.1473. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.